Response to crizotinib in advanced intrahepatic cholangiocarcinoma with ZKSCAN1-MET fusion and MET amplification: case reports and literature review

Response to crizotinib in advanced intrahepatic cholangiocarcinoma with ZKSCAN1-MET fusion and MET amplification: case reports and literature review

Abstract Intrahepatic cholangiocarcinoma (ICC) is the second most prevalent liver cancer after hepatocellular carcinoma and is characterized by high malignancy and poor prognosis. Gemcitabine combined with cisplatin is the standard first-line therapy for metastatic or unresectable ICC. The combinati...

Full description

Saved in:
Bibliographic Details
Main Authors: Jian-Hui Wu, Yu-ze Fan, Jing Sun, Xue-Zhang Duan
Format: Article
Language:English
Published: Springer 2025-06-01
Series:Discover Oncology
Subjects:
MET gene
Met mutations
Intrahepatic cholangiocarcinoma
Targeted therapy
Crizotinib
Online Access:https://doi.org/10.1007/s12672-025-02930-4
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1007/s12672-025-02930-4

Similar Items